Intellectual Property
Recognizing the importance of intellectual property in our industry, we have aggressively pursued patent protection in the U.S. and significant markets around the world for all of our products, as well as for products under development.
Our portfolio of intellectual property developed, licensed or acquired to date includes over 400 issued and pending U.S. patent applications, as of June 2009. In addition, strategic alliances with industry partners in clinical studies, production, marketing and distribution of our technology has resulted in not only out-licensing of the Company's patents and patent applications, but mutually beneficial cross-licensing and in-licensing of technology.
Our patents and patent applications relate to, among other things:
- the use of paclitaxel and other agents for the treatment of chronic inflammatory diseases, such as restenosis (including as a stent component), rheumatoid arthritis and psoriasis;
- compositions of and use of pharmacologic agents as medical device coatings and drug-eluting biomaterials;
- hybrid polymer systems designed for localized delivery of bioactive agents and controlled elution of drugs from medical device surfaces;
- non-reactive hydrophilic/hydrophobic polymer matrix, which can be varied to optimize performance characteristics such as lubricity, flexibility and hydration;
- biocompatible surface treatments used in ultrasound imaging technology to cause medical devices to shine brightly in ultrasound images providing greater echogenicity, or visibility;
- hemostatic and sealant compositions, as well as broad intellectual property rights relating to collagen;
- drug delivery compositions, such as our proprietary systemic formulation, medical device coatings and other local drug delivery systems; and
- methods of administration.
About Us
Quick Links
© Copyright 2011 Angiotech. All Rights Reserved.